Pharvaris (PHVS) Provides Business Update, Expands Development Program for Deucrictibant

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CRWV
10. CME

Go back to Pharvaris (PHVS) Provides Business Update, Expands Development Program for Deucrictibant

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

September 5, 2024 6:50 AM UTC

CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET

ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) --... More